{"id":55531,"date":"2023-04-05T12:04:27","date_gmt":"2023-04-05T10:04:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/adeno-associated-virus-vector-manufacturing-global-market-report-2023-robust-pipelines-for-gene-therapies-and-vaccines-bolsters-sector-researchandmarkets-com\/"},"modified":"2023-04-05T12:04:27","modified_gmt":"2023-04-05T10:04:27","slug":"adeno-associated-virus-vector-manufacturing-global-market-report-2023-robust-pipelines-for-gene-therapies-and-vaccines-bolsters-sector-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/adeno-associated-virus-vector-manufacturing-global-market-report-2023-robust-pipelines-for-gene-therapies-and-vaccines-bolsters-sector-researchandmarkets-com\/","title":{"rendered":"Adeno Associated Virus Vector Manufacturing Global Market Report 2023: Robust Pipelines for Gene Therapies and Vaccines Bolsters Sector – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By Therapeutic Area, By Region, And Segment Forecasts, 2023 – 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.<\/p>\n

<\/a><\/p>\n

\nThe global adeno associated virus vector manufacturing market size is expected to reach USD 3.95 billion by 2030, registering a CAGR of 22.5% over the forecast period.<\/p>\n

\nThis growth is attributed to the increasing prevalence of chronic diseases like cancers, cystic fibrosis, Duchenne muscular dystrophy, retinitis pigmentosa, and many more. AAV vector plays a vital role in the treatment of these diseases. AAV vectors also have a wide range of applications in gene therapy delivery. Companies are engaged in collaborations, mergers, and partnerships for innovative product launches with advancements in R&D.<\/p>\n

\nFor instance, in December 2021, Astellas and Dyno Therapeutics entered into a strategic collaboration to develop an NGS-based AAV vector for gene therapy by using Dyno’s CapsidMap platform for cardiac and skeletal muscle. Such initiatives are expected to expand their market presence in the development and production of antibodies, which is likely to support the growth of the market. The COVID-19 pandemic had a positive impact on the industry. As adeno associated virus has vast applications in vaccine manufacturing, various companies were involved in the race to manufacture the vaccine to treat COVID-19. This resulted in a sudden spur in the demand for manufacturing these vectors.<\/p>\n

\nFor instance, in September 2021, CEVEC and UCB entered into a strategic agreement for the use of ELEVECTA AAV vector manufacturing technology for R&D and gene therapy applications. As gene therapy involves alterations or modifications in the set of genes, it has raised many ethical issues.<\/p>\n

\nAs a result, the U.S. government restricted the usage of federal funds for research on germline gene therapy in people. Gene therapy can help save future generations of a family from acquiring a particular genetic disorder. However, it is anticipated to affect the fetus’s development significantly. The high demand for vaccines, gene therapeutics, CGMP drugs, and products to treat & cure acute diseases and the demand for improving patient care also propel the industry growth. Thus, global stakeholders are investing significantly in expanding their production capacities to fulfill the growing demands.<\/p>\n

\nAdeno Associated Virus Vector Manufacturing Market Report Highlights<\/strong><\/p>\n